Acrivon Therapeutics
Let the biomarker prove it
Acrivon Therapeutics is a clinical-stage precision oncology company built around its AP3 proteomics platform and drug-specific OncoSignature diagnostics.
The lead asset, ACR-368 (prexasertib, CHK1/2), is in a registrational‑intent Phase 2b for endometrial cancer with Fast Track for ACR‑368 and FDA Breakthrough Device designations for the OncoSignature assay.
Recent updates highlighted a 52% confirmed ORR in serous endometrial cancer across OncoSignature-positive and -negative subjects and a plan to run a prespecified simultaneous interim analysis of the serous all‑comer arms in the second half of 2026. ACR‑2316, a dual WEE1/PKMYT1 inhibitor, has early signs of activity and an ICI-combination rationale.
The company has moved its diagnostic testing in‑house via a newly certified CLIA laboratory, which, if ultimately paired with an on‑label companion diagnostic, could create a defensible “gatekeeper” for therapy access.
Financially, Acrivon reported a 2025 net loss of 77.9 million, ended 2025 with 118.6 million in cash and investments, and reported 97.7 million at March 31, 2026, with an added 7.3 million from an April 2026 ATM.
Management guides runway into the third quarter of 2027. TTM operating cash outflow is approximately 64.7 million (FY25 operating cash flow of −63.7 million plus Q1‑26 −20.5 million, minus Q1‑25 −19.5 million), with minimal capex.
Fully diluted shares outstanding were about 47.0 million as of March 31, 2026 (before the April ATM), and the company is seeking to expand its equity plan by 3.0 million shares, underscoring dilution risk typical for pre‑revenue biotech.
Our quality-first, long‑term framework therefore requires either decisive registrational data or the ability to acquire a stake near or below net cash per fully diluted share.
Does Acrivon Therapeutics have a strong competitive moat?
Moat assessment is prospective. Intangible assets: moderate. AP3 and drug‑specific OncoSignature diagnostics are proprietary, the ACR‑368 OncoSignature has FDA Breakthrough Device designations (ovarian and endometrial), and the company has established an internal CLIA lab to operate and evolve its diagnostics.
If the diagnostic is ultimately required on‑label, it can act as a gatekeeper. Score: 55. Switching costs: low-to-moderate. Oncologists can switch therapies, but if OncoSignature is embedded in care pathways and reimbursed as a companion diagnostic, frictions increase. Still unproven until marketing authorization.
Score: 30. Network effects: minimal. Data flywheel exists internally, but lacks two‑sided network dynamics. Score: 15. Cost advantages: limited. No obvious manufacturing or scale cost edge pre‑commercialization.
Score: 20. Efficient scale: niche tumor subtypes and a required diagnostic could limit entrant incentives in small indications, but broader markets remain competitive.
Score: 30. Weighted view: potential diagnostic gatekeeping and IP are real but contingent on successful registrational outcomes and regulatory decisions; Lilly license terms show freedom to partner but also future milestone and royalty obligations. Overall moat score: 40.
Does Acrivon Therapeutics have pricing power in its industry?
Observed pricing power is absent pre‑approval, but potential is meaningful. If ACR‑368 delivers confirmatory efficacy in a high‑mortality endometrial cancer subset with a required diagnostic, U.S. oncology pricing norms could support robust gross margins.
The diagnostic pairing and Fast Track/Breakthrough Device status may reduce payer friction if clinical benefit is clear. Latent pricing power is therefore moderate-to-high in a success case, but entirely binary on clinical and regulatory outcomes.
How predictable is Acrivon Therapeutics's business?
Revenue and free cash flow have no predictability at this stage. Clinical milestones are the primary drivers, with a prespecified interim analysis for the serous all‑comer arms slated for the second half of 2026 and Phase 3 readiness targeted by mid‑2026. Competitive and regulatory risks remain elevated, and timelines are subject to change.
This profile is the opposite of the toll‑booth economics we prefer for long‑term compounding.
Is Acrivon Therapeutics financially strong?
Strengths: no material debt and cash runway into Q3‑2027 provide operational visibility across multiple data catalysts. Weaknesses: persistent negative free cash flow and reliance on external capital.
Reported figures: FY‑2025 net loss 77.9 million; cash and investments 118.6 million at Dec 31, 2025; 97.7 million at Mar 31, 2026; ATM proceeds 7.3 million in April 2026; TTM operating cash outflow approximately 64.7 million. Capex is minimal. Net liquidity is adequate but sensitive to trial scale‑up and any delays.
How effective is Acrivon Therapeutics's capital allocation strategy?
Positive: a 2024 PIPE raised roughly 130 million at a premium to market, extending runway; CLIA build‑out internalizes a critical capability that could be a long‑term asset.
Neutral-to-negative: an April 2026 ATM at lower prices raised 7.3 million and the company seeks to add 3.0 million shares to its 2022 equity plan, reflecting ongoing dilution needs. R&D focus and the expiration of Lilly’s right of first negotiation in 2025 provide optionality to partner if data cooperate.
Overall, execution is pragmatic for a small biotech, but shareholder dilution risk is notable.
Does Acrivon Therapeutics have high-quality management?
Founder‑CEO Peter Blume‑Jensen, M.D., Ph.D., is the inventor of AP3 and OncoSignature and has deep oncology R&D experience at major pharma and prior diagnostics leadership, aligning expertise with the company’s strategic edge. The team has advanced two clinical programs and built an internal CLIA lab.
Governance watch‑items include ongoing equity compensation expansion typical of the sector. Net, we view management as scientifically strong and execution‑focused, with incentives aligned to clinical success.
Is Acrivon Therapeutics a quality company?
Acrivon Therapeutics is a weak quality company with a quality score of 41/100
- Drug-diagnostic pairing: ACR‑368 plus OncoSignature has FDA Fast Track (drug) and Breakthrough Device (diagnostic), with the assay now being brought in‑house under CLIA to streamline development and potentially strengthen future commercial defensibility if approved.
- Clinical momentum: Interim data show a 52% confirmed ORR in serous endometrial cancer and a prespecified simultaneous interim look for both serous all‑comer arms in 2H26, while ACR‑2316 demonstrates early monotherapy activity and mechanistic synergy with ICIs.
- Runway and burn: Cash, equivalents and investments of 97.7 million at March 31, 2026 plus 7.3 million from an April 2026 ATM support operations into Q3‑2027; TTM operating outflow around 64.7 million implies continued financing dependence absent partnerships.
- Competitive landscape: Multiple WEE1 and PKMYT1 programs are advancing (e.g., Zentalis azenosertib; Repare lunresertib), raising the bar for ACR‑2316 differentiation and combination data.
- Dilution vigilance: A 3.0 million increase proposed for the 2022 equity plan and use of the ATM reflect standard biotech financing playbooks; disciplined entry requires a margin of safety around net cash.
What is the fair value of Acrivon Therapeutics stock?
Is Acrivon Therapeutics a good investment at $1.49?
The following analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment advice, or a recommendation to buy or sell any security. The opinions expressed are based on publicly available information and historical data. Beanvest and its contributors may hold positions in the securities mentioned. Investors should conduct their own due diligence or consult a licensed financial advisor before making any investment decision.